TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Comparison of the Efficacy of Antiarrhythmic Drug Therapy and Radiofrequency Catheter Ablation for the Maintenance of Sinus Rhythm In Patients With Paroxysmal Atrial Fibrillation
Brief Summary: The purpose of this study is to compare radiofrequency catheter ablation and antiarrhythmic drug treatment for the maintenance of sinus rhythm in paroxysmal atrial fibrillation patients.


Options:
A: Arm Label: PVI + Lines Ablation; Type: EXPERIMENTAL; Interventions: Procedure: PVI + Lines ablation | Arm Label: PVI Ablation; Type: ACTIVE_COMPARATOR; Interventions: Procedure: PVI | Arm Label: PVI + CFE; Type: EXPERIMENTAL; Interventions: Procedure: PVI + CFE ablation | Intervention Type: PROCEDURE; Name: PVI + Lines ablation; Assigned to Arm(s): PVI + Lines Ablation | Intervention Type: PROCEDURE; Name: PVI; Assigned to Arm(s): PVI Ablation | Intervention Type: PROCEDURE; Name: PVI + CFE ablation; Assigned to Arm(s): PVI + CFE
B: Arm Label: medical therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: ACE inhibitor - ramipril, enalapril, captopril, perindopril, lisinopril, Drug: Beta Blocker (BB) - metoprolol, bisoprolol, carvedilol, Drug: Aldosterone Antagonists - spironolactone | Arm Label: Radiofrequency ablation (RFA); Type: ACTIVE_COMPARATOR; Interventions: Procedure: radiofrequency ablation | Intervention Type: PROCEDURE; Name: radiofrequency ablation; Assigned to Arm(s): Radiofrequency ablation (RFA) | Intervention Type: DRUG; Name: ACE inhibitor - ramipril, enalapril, captopril, perindopril, lisinopril; Assigned to Arm(s): medical therapy | Intervention Type: DRUG; Name: Beta Blocker (BB) - metoprolol, bisoprolol, carvedilol; Assigned to Arm(s): medical therapy | Intervention Type: DRUG; Name: Aldosterone Antagonists - spironolactone; Assigned to Arm(s): medical therapy
C: Intervention Type: PROCEDURE; Name: Circumferential Pulmonary Vein Ablation; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Antiarrhythmic Drug Therapy; Assigned to Arm(s): N/A
D: Arm Label: Drug Treatment; Type: ACTIVE_COMPARATOR; Interventions: Device: Radiofrequency ablation, antiarrhythmic drugs, Drug: Amiodarone, flecainide, propafenone, quinidine, dofetilide, sotalol, cibenzoline, beta blocking and calcium channel blocking agents and antiarrhythmic drugs | Arm Label: ThermoCool Radiofrequency Catheter; Type: ACTIVE_COMPARATOR; Interventions: Device: Radiofrequency ablation, antiarrhythmic drugs, Device: ThermoCool Radiofrequency Catheter | Intervention Type: DEVICE; Name: Radiofrequency ablation, antiarrhythmic drugs; Assigned to Arm(s): Drug Treatment, ThermoCool Radiofrequency Catheter | Intervention Type: DRUG; Name: Amiodarone, flecainide, propafenone, quinidine, dofetilide, sotalol, cibenzoline, beta blocking and calcium channel blocking agents and antiarrhythmic drugs; Assigned to Arm(s): Drug Treatment | Intervention Type: DEVICE; Name: ThermoCool Radiofrequency Catheter; Assigned to Arm(s): ThermoCool Radiofrequency Catheter

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Comparison of the Efficacy of Antiarrhythmic Drug Therapy and Radiofrequency Catheter Ablation for the Maintenance of Sinus Rhythm In Patients With Paroxysmal Atrial Fibrillation
Brief Summary: The purpose of this study is to compare radiofrequency catheter ablation and antiarrhythmic drug treatment for the maintenance of sinus rhythm in paroxysmal atrial fibrillation patients.


Options:
A: Arm Label: NAVISTAR® THERMOCOOL® Catheter; Type: EXPERIMENTAL; Interventions: Device: NAVISTAR® THERMOCOOL® Catheter | Arm Label: Antiarrhythmic drug; Type: ACTIVE_COMPARATOR; Interventions: Drug: Antiarrhythmic drug | Intervention Type: DEVICE; Name: NAVISTAR® THERMOCOOL® Catheter; Assigned to Arm(s): NAVISTAR® THERMOCOOL® Catheter | Intervention Type: DRUG; Name: Antiarrhythmic drug; Assigned to Arm(s): Antiarrhythmic drug
B: Arm Label: Atrial Fibrillation Ablation; Type: EXPERIMENTAL; Interventions: Procedure: Atrial fibrillation ablation | Arm Label: Drug therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Antiarrhythmic drug | Intervention Type: PROCEDURE; Name: Atrial fibrillation ablation; Assigned to Arm(s): Atrial Fibrillation Ablation | Intervention Type: DRUG; Name: Antiarrhythmic drug; Assigned to Arm(s): Drug therapy
C: Arm Label: Dormant PV conduction; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Additional ablation until elimination of dormant conduction, Procedure: No additional ablation | Arm Label: No dormant PV conduction; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Registry group, Procedure: Usual medical care | Intervention Type: PROCEDURE; Name: Additional ablation until elimination of dormant conduction; Assigned to Arm(s): Dormant PV conduction | Intervention Type: PROCEDURE; Name: No additional ablation; Assigned to Arm(s): Dormant PV conduction | Intervention Type: PROCEDURE; Name: Registry group; Assigned to Arm(s): No dormant PV conduction | Intervention Type: PROCEDURE; Name: Usual medical care; Assigned to Arm(s): No dormant PV conduction
D: Arm Label: Drug Treatment; Type: ACTIVE_COMPARATOR; Interventions: Device: Radiofrequency ablation, antiarrhythmic drugs, Drug: Amiodarone, flecainide, propafenone, quinidine, dofetilide, sotalol, cibenzoline, beta blocking and calcium channel blocking agents and antiarrhythmic drugs | Arm Label: ThermoCool Radiofrequency Catheter; Type: ACTIVE_COMPARATOR; Interventions: Device: Radiofrequency ablation, antiarrhythmic drugs, Device: ThermoCool Radiofrequency Catheter | Intervention Type: DEVICE; Name: Radiofrequency ablation, antiarrhythmic drugs; Assigned to Arm(s): Drug Treatment, ThermoCool Radiofrequency Catheter | Intervention Type: DRUG; Name: Amiodarone, flecainide, propafenone, quinidine, dofetilide, sotalol, cibenzoline, beta blocking and calcium channel blocking agents and antiarrhythmic drugs; Assigned to Arm(s): Drug Treatment | Intervention Type: DEVICE; Name: ThermoCool Radiofrequency Catheter; Assigned to Arm(s): ThermoCool Radiofrequency Catheter

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Treatment Adherence and Compliance in Children and Adolescents on ADHD Medication and Emotional Expression in Clinical Practice
Brief Summary: The primary research objective of this observational study is to evaluate treatment compliance over one year in children and adolescents who are newly initiated on medication approved for the treatment of ADHD in a routine clinical setting. Compliance will be assessed using the Pediatric Compliance Self-Rating (PCSR) Instrument. A patient will be considered as compliant at a given visit, if the PCSR score is at least 5, corresponding to taking the medication at least often.


Options:
A: Arm Label: A; Type: N/A; Interventions: Drug: Atomoxetine | Arm Label: B; Type: N/A; Interventions: Drug: stimulants (any approved ADHD medication) | Intervention Type: DRUG; Name: Atomoxetine; Assigned to Arm(s): A | Intervention Type: DRUG; Name: stimulants (any approved ADHD medication); Assigned to Arm(s): B
B: Arm Label: Methylphenidate transdermal system; Type: EXPERIMENTAL; Interventions: Drug: Methylphenidate Transdermal System | Intervention Type: DRUG; Name: Methylphenidate Transdermal System; Assigned to Arm(s): Methylphenidate transdermal system
C: Arm Label: Active; Type: EXPERIMENTAL; Interventions: Drug: Quillivant Oral Suspension XR, Drug: Placebo | Arm Label: Comparator; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Quillivant Oral Suspension XR; Assigned to Arm(s): Active | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Active | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Comparator
D: Intervention Type: DRUG; Name: Methylphenidate; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase III Comparative, Open-labelled, Randomised, Clinical Study to Assess a Fixed Dose of Oral Pyronaridine Artesunate Granule Formulation vs. Coartem® Crushed Tablets in Infants With Acute Uncomplicated Plasmodium Falciparum Malaria
Brief Summary: The primary objective of this Phase III clinical study is to demonstrate the efficacy of the fixed combination of pyronaridine artesunate (PA) granule formulation (60:20 mg; pediatric PYRAMAX®) by showing a PCR-corrected adequate clinical and parasitological cure rate (ACPR) of more than 90%.

Secondary objectives of this clinical study are to compare the efficacy (non-inferiority) and safety of the PA granule formulation compared to Coartem® (ie, the combination of artemether/lumefantrine \[AL\]) crushed tablets in a paediatric population and to assess the safety of the PA granule formulation.


Options:
A: Arm Label: Group A (Tablets); Type: EXPERIMENTAL; Interventions: Drug: Pyronaridine-Artesunate | Arm Label: Group B (Tablets); Type: EXPERIMENTAL; Interventions: Drug: Pyronaridine-Artesunate | Arm Label: Group C (Tablets); Type: EXPERIMENTAL; Interventions: Drug: Pyronaridine-Artesunate | Arm Label: Group D (Granules); Type: EXPERIMENTAL; Interventions: Drug: Pyronaridine-Artesunate | Intervention Type: DRUG; Name: Pyronaridine-Artesunate; Assigned to Arm(s): Group A (Tablets), Group B (Tablets), Group C (Tablets), Group D (Granules)
B: Arm Label: PA group; Type: EXPERIMENTAL; Interventions: Drug: pyronaridine artesunate | Arm Label: AL group; Type: ACTIVE_COMPARATOR; Interventions: Drug: arthemeter lumefantrine | Intervention Type: DRUG; Name: pyronaridine artesunate; Assigned to Arm(s): PA group | Intervention Type: DRUG; Name: arthemeter lumefantrine; Assigned to Arm(s): AL group
C: Arm Label: Pyronaridine - artesunate; Type: EXPERIMENTAL; Interventions: Drug: Pyronaridine - artesunate | Arm Label: Mefloquine plus artesunate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mefloquine plus artesunate | Intervention Type: DRUG; Name: Pyronaridine - artesunate; Assigned to Arm(s): Pyronaridine - artesunate | Intervention Type: DRUG; Name: Mefloquine plus artesunate; Assigned to Arm(s): Mefloquine plus artesunate
D: Arm Label: arm 1; Type: EXPERIMENTAL; Interventions: Drug: Artesunate | Arm Label: arm 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Artesunate + Mefloquine | Intervention Type: DRUG; Name: Artesunate; Assigned to Arm(s): arm 1 | Intervention Type: DRUG; Name: Artesunate + Mefloquine; Assigned to Arm(s): arm 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase III Comparative, Open-labelled, Randomised, Clinical Study to Assess a Fixed Dose of Oral Pyronaridine Artesunate Granule Formulation vs. Coartem® Crushed Tablets in Infants With Acute Uncomplicated Plasmodium Falciparum Malaria
Brief Summary: The primary objective of this Phase III clinical study is to demonstrate the efficacy of the fixed combination of pyronaridine artesunate (PA) granule formulation (60:20 mg; pediatric PYRAMAX®) by showing a PCR-corrected adequate clinical and parasitological cure rate (ACPR) of more than 90%.

Secondary objectives of this clinical study are to compare the efficacy (non-inferiority) and safety of the PA granule formulation compared to Coartem® (ie, the combination of artemether/lumefantrine \[AL\]) crushed tablets in a paediatric population and to assess the safety of the PA granule formulation.


Options:
A: Arm Label: PA group; Type: EXPERIMENTAL; Interventions: Drug: pyronaridine artesunate | Arm Label: AL group; Type: ACTIVE_COMPARATOR; Interventions: Drug: arthemeter lumefantrine | Intervention Type: DRUG; Name: pyronaridine artesunate; Assigned to Arm(s): PA group | Intervention Type: DRUG; Name: arthemeter lumefantrine; Assigned to Arm(s): AL group
B: Arm Label: Pyronaridine - artesunate; Type: EXPERIMENTAL; Interventions: Drug: Pyronaridine - artesunate | Arm Label: Mefloquine plus artesunate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mefloquine plus artesunate | Intervention Type: DRUG; Name: Pyronaridine - artesunate; Assigned to Arm(s): Pyronaridine - artesunate | Intervention Type: DRUG; Name: Mefloquine plus artesunate; Assigned to Arm(s): Mefloquine plus artesunate
C: Arm Label: Pyronaridine-artesunate; Type: EXPERIMENTAL; Interventions: Drug: Pyronaridine-artesunate | Intervention Type: DRUG; Name: Pyronaridine-artesunate; Assigned to Arm(s): Pyronaridine-artesunate
D: Arm Label: PA group; Type: EXPERIMENTAL; Interventions: Drug: Pyronaridine artesunate | Arm Label: AL group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Coartem® (artemether lumefantrine) | Intervention Type: DRUG; Name: Pyronaridine artesunate; Assigned to Arm(s): PA group | Intervention Type: DRUG; Name: Coartem® (artemether lumefantrine); Assigned to Arm(s): AL group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase III Comparative, Open-labelled, Randomised, Clinical Study to Assess a Fixed Dose of Oral Pyronaridine Artesunate Granule Formulation vs. Coartem® Crushed Tablets in Infants With Acute Uncomplicated Plasmodium Falciparum Malaria
Brief Summary: The primary objective of this Phase III clinical study is to demonstrate the efficacy of the fixed combination of pyronaridine artesunate (PA) granule formulation (60:20 mg; pediatric PYRAMAX®) by showing a PCR-corrected adequate clinical and parasitological cure rate (ACPR) of more than 90%.

Secondary objectives of this clinical study are to compare the efficacy (non-inferiority) and safety of the PA granule formulation compared to Coartem® (ie, the combination of artemether/lumefantrine \[AL\]) crushed tablets in a paediatric population and to assess the safety of the PA granule formulation.


Options:
A: Intervention Type: DRUG; Name: Artemether-lumefantrine; Assigned to Arm(s): N/A
B: Arm Label: Eurartesim dispersible oral tablets; Type: EXPERIMENTAL; Interventions: Drug: Eurartesim dispersible oral tablet | Arm Label: Eurartesim film coated tablet; Type: ACTIVE_COMPARATOR; Interventions: Drug: eurartesim film coated tablet | Intervention Type: DRUG; Name: Eurartesim dispersible oral tablet; Assigned to Arm(s): Eurartesim dispersible oral tablets | Intervention Type: DRUG; Name: eurartesim film coated tablet; Assigned to Arm(s): Eurartesim film coated tablet
C: Arm Label: PA group; Type: EXPERIMENTAL; Interventions: Drug: pyronaridine artesunate | Arm Label: AL group; Type: ACTIVE_COMPARATOR; Interventions: Drug: arthemeter lumefantrine | Intervention Type: DRUG; Name: pyronaridine artesunate; Assigned to Arm(s): PA group | Intervention Type: DRUG; Name: arthemeter lumefantrine; Assigned to Arm(s): AL group
D: Arm Label: co-formulated Amodiaquine-Artesunate; Type: ACTIVE_COMPARATOR; Interventions: Drug: amodiaquine-artesunate (AQAS) fixed-dose | Arm Label: artemether-lumefantrine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Artemether-lumefantrine combination (AL) dispersable | Intervention Type: DRUG; Name: amodiaquine-artesunate (AQAS) fixed-dose; Assigned to Arm(s): co-formulated Amodiaquine-Artesunate | Intervention Type: DRUG; Name: Artemether-lumefantrine combination (AL) dispersable; Assigned to Arm(s): artemether-lumefantrine

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase III Comparative, Open-labelled, Randomised, Clinical Study to Assess a Fixed Dose of Oral Pyronaridine Artesunate Granule Formulation vs. Coartem® Crushed Tablets in Infants With Acute Uncomplicated Plasmodium Falciparum Malaria
Brief Summary: The primary objective of this Phase III clinical study is to demonstrate the efficacy of the fixed combination of pyronaridine artesunate (PA) granule formulation (60:20 mg; pediatric PYRAMAX®) by showing a PCR-corrected adequate clinical and parasitological cure rate (ACPR) of more than 90%.

Secondary objectives of this clinical study are to compare the efficacy (non-inferiority) and safety of the PA granule formulation compared to Coartem® (ie, the combination of artemether/lumefantrine \[AL\]) crushed tablets in a paediatric population and to assess the safety of the PA granule formulation.


Options:
A: Arm Label: pyronaridine/artesunate (6:2 mg/kg); Type: EXPERIMENTAL; Interventions: Drug: pyronaridine/artesunate | Arm Label: pyronaridine/artesunate (9:3 mg/kg); Type: EXPERIMENTAL; Interventions: Drug: pyronaridine/artesunate | Arm Label: pyronaridine/artesunate (12:4 mg/kg); Type: EXPERIMENTAL; Interventions: Drug: pyronaridine/artesunate | Intervention Type: DRUG; Name: pyronaridine/artesunate; Assigned to Arm(s): pyronaridine/artesunate (12:4 mg/kg), pyronaridine/artesunate (6:2 mg/kg), pyronaridine/artesunate (9:3 mg/kg)
B: Arm Label: Pyronaridine - artesunate; Type: EXPERIMENTAL; Interventions: Drug: Pyronaridine - artesunate | Arm Label: Mefloquine plus artesunate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mefloquine plus artesunate | Intervention Type: DRUG; Name: Pyronaridine - artesunate; Assigned to Arm(s): Pyronaridine - artesunate | Intervention Type: DRUG; Name: Mefloquine plus artesunate; Assigned to Arm(s): Mefloquine plus artesunate
C: Arm Label: pyronaridine artesunate; Type: EXPERIMENTAL; Interventions: Drug: Pyronaridine artesunate | Arm Label: chloroquine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chloroquine | Intervention Type: DRUG; Name: Pyronaridine artesunate; Assigned to Arm(s): pyronaridine artesunate | Intervention Type: DRUG; Name: Chloroquine; Assigned to Arm(s): chloroquine
D: Arm Label: PA group; Type: EXPERIMENTAL; Interventions: Drug: pyronaridine artesunate | Arm Label: AL group; Type: ACTIVE_COMPARATOR; Interventions: Drug: arthemeter lumefantrine | Intervention Type: DRUG; Name: pyronaridine artesunate; Assigned to Arm(s): PA group | Intervention Type: DRUG; Name: arthemeter lumefantrine; Assigned to Arm(s): AL group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Non-inferiority Comparison of 35 mg Delayed-release Risedronate, Given Once-weekly Either Before or After Breakfast, & 5 mg Immediate-release Risedronate, Given Once-daily Before Breakfast, in the Treatment of Postmenopausal Osteoporosis.
Brief Summary: The purpose of this trial is to study the efficacy of a 35 mg delayed release weekly dosing regimen as compared to the standard daily dosing regimen of risedronate 5 mg daily.


Options:
A: Arm Label: Genistein vs. Risedronate; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Genistein vs Risedronate | Arm Label: Genistein dose and source; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Genistein vs Risedronate | Intervention Type: DIETARY_SUPPLEMENT; Name: Genistein vs Risedronate; Assigned to Arm(s): Genistein dose and source, Genistein vs. Risedronate
B: Arm Label: 5 mg Before Breakfast; Type: ACTIVE_COMPARATOR; Interventions: Drug: risedronate | Arm Label: 35 mg After Breakfast; Type: EXPERIMENTAL; Interventions: Drug: risedronate | Arm Label: 35 mg Before Breakfast; Type: EXPERIMENTAL; Interventions: Drug: risedronate | Intervention Type: DRUG; Name: risedronate; Assigned to Arm(s): 5 mg Before Breakfast | Intervention Type: DRUG; Name: risedronate; Assigned to Arm(s): 35 mg After Breakfast | Intervention Type: DRUG; Name: risedronate; Assigned to Arm(s): 35 mg Before Breakfast
C: Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Calcium Carbonate, Drug: Vitamin D3 | Arm Label: Risedronate; Type: EXPERIMENTAL; Interventions: Drug: Calcium Carbonate, Drug: Vitamin D3, Drug: Risedronate | Arm Label: Exercise; Type: EXPERIMENTAL; Interventions: Drug: Calcium Carbonate, Drug: Vitamin D3, Behavioral: Bone-loading exercises | Intervention Type: DRUG; Name: Calcium Carbonate; Assigned to Arm(s): Control, Exercise, Risedronate | Intervention Type: DRUG; Name: Vitamin D3; Assigned to Arm(s): Control, Exercise, Risedronate | Intervention Type: DRUG; Name: Risedronate; Assigned to Arm(s): Risedronate | Intervention Type: BEHAVIORAL; Name: Bone-loading exercises; Assigned to Arm(s): Exercise
D: Intervention Type: DRUG; Name: MK0217, alendronate sodium/Duration of Intervention: 12 mo; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Comparator: risedronate / Duration of Intervention: 12 mo; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of the Safety and Immunogenicity of GSK Biologicals' HPV Vaccine 580299 When Administered in Healthy Females Aged 9 - 25 Years Using an Alternative Schedule and an Alternative Dosing as Compared to the Standard Schedule and Dosing
Brief Summary: Human Papillomavirus (HPV) infection has been established as a necessary cause of cervical cancer. GlaxoSmithKline (GSK) Biologicals has developed an HPV vaccine (580299) which targets the 2 most common oncogenic HPV types (HPV-16 and HPV-18), found in approximately 70% of all cervical cancers. In previous trials this vaccine has been found to be efficacious in the prevention of incident and persistent HPV-16/18 infections and associated cytological abnormalities and cervical dysplasia. In this partially-blind study, GSK Biologicals will evaluate the safety and immunogenicity of the HPV vaccine using an alternative schedule and an alternative dosing when administered in healthy young females aged 9 to 25 years, as compared to the standard HPV vaccine. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007. The protocol posting has been updated following a protocol amendment.


Options:
A: Arm Label: 12 months; Type: EXPERIMENTAL; Interventions: Biological: quadrivalent human papillomavirus vaccine | Arm Label: 6 month; Type: ACTIVE_COMPARATOR; Interventions: Biological: quadrivalent human papillomavirus vaccine | Intervention Type: BIOLOGICAL; Name: quadrivalent human papillomavirus vaccine; Assigned to Arm(s): 12 months | Intervention Type: BIOLOGICAL; Name: quadrivalent human papillomavirus vaccine; Assigned to Arm(s): 6 month
B: Arm Label: Cervarix Group; Type: EXPERIMENTAL; Interventions: Biological: HPV GSK 580299 vaccine | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo control | Intervention Type: BIOLOGICAL; Name: HPV GSK 580299 vaccine; Assigned to Arm(s): Cervarix Group | Intervention Type: BIOLOGICAL; Name: Placebo control; Assigned to Arm(s): Placebo Group
C: N/A
D: Arm Label: Cervarix 1/Placebo Group; Type: EXPERIMENTAL; Interventions: Biological: Cervarix, Drug: Placebo | Arm Label: Cervarix 1/Placebo/Cervarix 1 Group; Type: EXPERIMENTAL; Interventions: Biological: Cervarix, Drug: Placebo | Arm Label: Cervarix 2/Placebo/Cervarix 2 Group; Type: EXPERIMENTAL; Interventions: Biological: Cervarix, Drug: Placebo | Arm Label: Cervarix 2 Group; Type: EXPERIMENTAL; Interventions: Biological: Cervarix | Intervention Type: BIOLOGICAL; Name: Cervarix; Assigned to Arm(s): Cervarix 1/Placebo Group, Cervarix 1/Placebo/Cervarix 1 Group, Cervarix 2 Group, Cervarix 2/Placebo/Cervarix 2 Group | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cervarix 1/Placebo Group, Cervarix 1/Placebo/Cervarix 1 Group, Cervarix 2/Placebo/Cervarix 2 Group

Answer: D